France-based Cytheris, a pharmaceutical company developing new therapies for the immune system, has raised EUR 24.3m from CDC Entreprises Innovation, ABN Amro Capital Life Sciences and its historical investors.
Target Global I closed on €300m in 2015 and is now fully deployed
Existing investor Redalpine also participates in the round for the online ticketing platform
Deal is Sortera's 13th acquisition since it was established in 2006
Alpina began its ERP software buy-and-build platform with the acquisition of Oxaion in 2015